Regional Decolonization Aids Multidrug-Resistant Organism-Related Outcomes
By Lori Solomon HealthDay Reporter
MONDAY, April 1, 2024 -- A regional collaborative involving universal decolonization in long-term care facilities and targeted decolonization among hospital patients in contact precautions is associated with better multidrug-resistant organism (MDRO)-related outcomes, according to a study published online April 1 in the Journal of the American Medical Association.
Gabrielle M. Gussin, from the University of California Irvine School of Medicine, and colleagues evaluated whether implementation of a decolonization collaborative is associated with reduced regional MDRO prevalence, incident clinical cultures, infection-related hospitalizations, costs, and deaths. The analysis included data from 35 participating facilities (16 hospitals, 16 nursing homes [NHs], and three long-term acute care hospitals [LTACHs]).
The researchers found that compared with baseline, decolonization was associated with a decrease in mean MDRO prevalence (NHs: 63.9 to 49.9 percent; LTACHs: 80.0 to 53.3 percent; odds ratio for both, 0.48; hospitalized patients in contact precautions: 64.1 to 55.4 percent; odds ratio, 0.75). Mean monthly incident MDRO clinical cultures changed from 2.7 to 1.7 among participating NHs, from 1.7 to 1.5 among nonparticipating NHs (group × period interaction reduction, 30.4 percent), and from 25.5 to 25.0 among participating hospitals and 12.5 to 14.3 among nonparticipating hospitals (group × period interaction reduction, 12.9 percent). Benefits were seen for infection-related hospitalizations, associated hospitalization costs, and associated hospitalization deaths.
"The success of SHIELD-OC [Shared Healthcare Intervention to Eliminate Life-threatening Dissemination of MDROs in Orange County] in reducing MDRO carriage, infections, hospitalizations, and associated costs and deaths led to a regional NH incentive program supported by CalOptima, the sole Medicaid provider," the authors write.
Antiseptic supplies for the study were provided by Stryker (Sage Products), Xttrium Laboratories, and Medline Industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Multisite QI Collaborative Increases Appropriate Pediatric Antibiotic Use
MONDAY, April 29, 2024 -- A multisite collaborative increases appropriate antibiotic use for pediatric community-acquired pneumonia, skin and soft tissue infections, and urinary...
ACP: Next-Generation Antibiotics Underused for Gram-Negative Infections
MONDAY, April 22, 2024 -- Clinicians frequently treat gram-negative infection with older, generic antibiotics, despite recent approval of next-generation, gram-negative...
H. Pylori Testing Feasible for People in Community Settings
THURSDAY, April 18, 2024 -- Community Helicobacter pylori (HP) testing in high-risk individuals is technically feasible, according to a study published online April 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.